These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21288478)

  • 1. Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
    Pardee TS; Zuber J; Lowe SW
    Exp Hematol; 2011 Apr; 39(4):473-485.e4. PubMed ID: 21288478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
    Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
    Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytarabine-Resistant
    Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
    Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
    Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
    Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
    Williams AB; Nguyen B; Li L; Brown P; Levis M; Leahy D; Small D
    Leukemia; 2013 Jan; 27(1):48-55. PubMed ID: 22858906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells.
    Wang R; Li Y; Gong P; Gabrilove J; Waxman S; Jing Y
    Mol Cancer Ther; 2018 Sep; 17(9):1871-1880. PubMed ID: 29959200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
    Damdinsuren A; Matsushita H; Ito M; Tanaka M; Jin G; Tsukamoto H; Asai S; Ando K; Miyachi H
    Leuk Res; 2015 Dec; 39(12):1405-13. PubMed ID: 26475207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
    Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
    Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
    Zorko NA; Bernot KM; Whitman SP; Siebenaler RF; Ahmed EH; Marcucci GG; Yanes DA; McConnell KK; Mao C; Kalu C; Zhang X; Jarjoura D; Dorrance AM; Heerema NA; Lee BH; Huang G; Marcucci G; Caligiuri MA
    Blood; 2012 Aug; 120(5):1130-6. PubMed ID: 22674806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
    Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
    Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
    Qiu QC; Wang C; Bao XB; Yang J; Shen HJ; Ding ZX; Liu H; He J; Yao H; Chen SN; Li Z; Xue SL; Liu SB
    Hematology; 2018 Apr; 23(3):131-138. PubMed ID: 28876197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.